Vaxcyte (PCVX) Other Accumulated Expenses (2019 - 2023)

Vaxcyte (PCVX) has 5 years of Other Accumulated Expenses data on file, last reported at $1.9 million in Q4 2023.

• On a quarterly basis, Other Accumulated Expenses rose 34.66% year-over-year to $1.9 million in Q4 2023; TTM through Dec 2023 was $1.9 million, a 34.66% increase from a year earlier, with the FY2023 full-year figure at $1.9 million, up 34.66% from the prior year.
• Other Accumulated Expenses for Q4 2023 stood at $1.9 million, down from $2.5 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for PCVX reached as high as $5.0 million in Q3 2021 and fell as low as $64000.0 in Q4 2019.
• Historically, Other Accumulated Expenses has averaged $1.8 million across 5 years, with a median of $1.5 million in 2022.
• Across the five-year window, Other Accumulated Expenses surged 1267.24% in 2021 and tumbled 76.67% in 2022, its largest moves.
• Year by year, Other Accumulated Expenses stood at $64000.0 in 2019, then soared by 575.0% to $432000.0 in 2020, then soared by 746.76% to $3.7 million in 2021, then sank by 61.43% to $1.4 million in 2022, then soared by 34.66% to $1.9 million in 2023.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $1.9 million in Q4 2023, $2.5 million in Q3 2023, and $1.9 million in Q2 2023.